Moreover, YAP/TAZ promotes hepatocyte proliferation and tumor growth upon Myc-β-catenin in hepatocellular carcinoma (HCC) [15] and mediates sorafenib resistance in HCC [16]. Here, YAP1 is linked to hepatocellular carcinoma.